Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by V Square Quantitative Management LLC

V Square Quantitative Management LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 28,796 shares of the biopharmaceutical company’s stock after purchasing an additional 1,622 shares during the period. V Square Quantitative Management LLC’s holdings in Gilead Sciences were worth $2,660,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in GILD. Bellevue Group AG boosted its position in shares of Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after buying an additional 7,093 shares during the period. Quantinno Capital Management LP boosted its holdings in Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after acquiring an additional 48,910 shares during the period. McAdam LLC boosted its holdings in Gilead Sciences by 16.7% during the 4th quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after acquiring an additional 3,627 shares during the period. IRON Financial LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $830,000. Finally, Capital Investment Advisors LLC increased its stake in Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after purchasing an additional 9,791 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GILD shares. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday. Morgan Stanley upped their price objective on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday. Bank of America reiterated a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Mizuho increased their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Thursday, November 21st. Eleven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $101.33.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 710,500 shares of company stock valued at $67,684,956 in the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $105.96 on Friday. The business has a 50 day simple moving average of $93.38 and a 200-day simple moving average of $87.24. The company has a market capitalization of $132.05 billion, a P/E ratio of 1,177.33, a PEG ratio of 1.25 and a beta of 0.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $106.43. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 4.35 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.